Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

OTLK holding history

Outlook Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

OTLK overviewAll 13F holders of OTLKFull Q2 2026 holdings

Shares (Q2 2026)
152,215
Value
$242.0K
% of portfolio
<0.1%
Quarters held
19
Since Q1 2021
Holdings of OTLK by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026152,215$242.0K<0.1%+19,146+14.4%AddedHolders
Q1 2026133,069$27.4K<0.1%−76,471−36.5%ReducedHolders
Q4 2025209,540$331.1K<0.1%+161,426+335.5%AddedHolders
Q3 202548,114$51.0K<0.1%−7,010−12.7%ReducedHolders
Q2 202555,124$88.2K<0.1%−39,479−41.7%ReducedHolders
Q1 202594,603$115.4K<0.1%−192,041−67.0%ReducedHolders
Q4 2024286,644$541.8K<0.1%+279,488+3,905.6%AddedHolders
Q3 20247,156$38.2K<0.1%+4,746+196.9%AddedHolders
Q2 20242,410$17.8K<0.1%−6,913−74.1%ReducedHolders
Q1 20249,323$111.3K<0.1%+3,032+48.2%AddedConverted for a 1-for-20 splitHolders
Q4 2023125,813$49.6K<0.1%+125,813NewHolders
Q3 20230$00.0%−5,035−100.0%Sold outHolders
Q2 20235,035$8.76K<0.1%−4,081−44.8%ReducedHolders
Q1 20239,116$9.94K<0.1%−9,065−49.9%ReducedHolders
Q4 202218,181$19.6K<0.1%+18,181NewHolders
Q3 20220$00.0%−1,438−100.0%Sold outHolders
Q2 20221,438$1.00K<0.1%−1,303−47.5%ReducedHolders
Q1 20222,741$5.00K<0.1%−29,148−91.4%ReducedHolders
Q4 202131,889$43.0K<0.1%+31,889NewHolders
Q3 20210$00.0%−5,072−100.0%Sold outHolders
Q2 20215,072$13.0K<0.1%−1,778−26.0%ReducedHolders
Q1 20216,850$15.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.